76
Views
0
CrossRef citations to date
0
Altmetric
Commentaries

Synergism between arsenic trioxide and aclacinomycin in acute myeloid leukemia

&

References

  • Conway O’Brien E, Prideaux S, Chevassut T. The epigenetic landscape of acute myeloid leukemia. Adv Hematol 2014;2014:103175.
  • Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood 2010;116:3147–3156.
  • Platanias LC. Biological responses to arsenic compounds. J Biol Chem 2009;284:18583–18587.
  • Breccia M, Cicconi L, Lo-Coco F. ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia? Curr Opin Hematol 2014;21:95–101.
  • Miller WH, Jr, Schipper HM, Lee JS, et al. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893–3903.
  • Takahashi S. Combination therapy with arsenic trioxide for hematological malignancies. Anti-Cancer Agents Med Chem 2010; 10:504–510.
  • Warrell RP, Jr. Aclacinomycin A: clinical development of a novel anthracycline antibiotic in the haematological cancers. Drugs Under Exp Clin Res 1986;12:275–282.
  • Bennett DC, Charest J, Sebolt K, et al. High-throughput screening identifies aclacinomycin as a radiosensitizer of EGFR-mutant non-small cell lung cancer. Transl Oncol 2013;6:382–391.
  • Nyoung MN, Trentesaux C, Aries A, et al. Effect of aclacinomycin-doxorubicin association on differentiation and growth of human erythroleukemic K562 cells. Anticancer Res 1994;14:1203–1208.
  • Song LX, Xu L, Li X, et al. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia. Ann Hematol 2012;91:1879–1886.
  • Ye Y, Xu X, Zhang M, et al. Low-dose Arsenic trioxide combined with aclacinomycin A synergistically enhance the cytotoxic effect on human acute myelogenous leukemia cell line by induction of apoptosis. Leuk lymphoma 2015;56:3162–3170.
  • Sato S, Sakashita A, Ishiyama T, et al. Possible differentiation treatment with aclacinomycin A in acute myelomonocytic leukemia refractory to conventional chemotherapy. Anticancer Res 1992;12: 371–376.
  • Hu XM, Yuan B, Tanaka S, et al. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines. Hematology 2014;19:352–360.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.